Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type
- PMID: 15973103
- PMCID: PMC1357706
- DOI: 10.1097/01.sla.0000167862.52309.7d
Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type
Abstract
Objective: To analyze tumor biology and the outcome of differentiated treatment in relation to tumor subtype in patients with gastric carcinoid.
Background: Gastric carcinoids may be subdivided into ECL cell carcinoids (type 1 associated with atrophic gastritis, type 2 associated with gastrinoma, type 3 without predisposing conditions) and miscellaneous types (type 4). The biologic behavior and prognosis vary considerably in relation to type.
Methods: A total of 65 patients from 24 hospitals (51 type 1, 1 type 2, 4 type 3, and 9 type 4) were included. Management recommendations were issued for newly diagnosed cases, that is, endoscopic or surgical treatment of type 1 and 2 carcinoids (including antrectomy to abolish hypergastrinemia) and radical resection for type 3 and 4 carcinoids.
Results: Infiltration beyond the submucosa occurred in 9 of 51 type 1, 4 of 4 type 3, and 7 of 9 type 4 carcinoids. Metastases occurred in 4 of 51 type 1 (3 regional lymph nodes, 1 liver), the single type 2 (regional lymph nodes), 3 of 4 type 3 (all liver), and 7 of 9 type 4 carcinoids (all liver). Of the patients with type 1 carcinoid, 3 had no specific treatment, 40 were treated with endoscopic or surgical excision (in 10 cases combined with antrectomy), 7 underwent total gastrectomy, and 1 underwent proximal gastric resection. Radical tumor removal was not possible in 2 of 4 patients with type 3 and 7 of 9 patients with type 4 carcinoid. Five- and 10-year crude survival rates were 96.1% and 73.9% for type 1 (not different from the general population), but only 33.3% and 22.2% for type 4 carcinoids.
Conclusion: Subtyping of gastric carcinoids is helpful in the prediction of malignant potential and long-term survival and is a guide to management. Long-term survival did not differ from that of the general population regarding type 1 carcinoids but was poor regarding type 4 carcinoids.
Figures
Similar articles
-
[Clinicopathological features and prognosis of different gastric carcinoid subtypes].Zhonghua Zhong Liu Za Zhi. 2008 Nov;30(11):866-9. Zhonghua Zhong Liu Za Zhi. 2008. PMID: 19173835 Chinese.
-
Management and clinical outcomes of type I gastric carcinoid patients: retrospective, multicenter study in Japan.Dig Endosc. 2014 May;26(3):377-84. doi: 10.1111/den.12197. Epub 2013 Nov 5. Dig Endosc. 2014. PMID: 24188531
-
Usefulness of laparoscope-assisted antrectomy for gastric carcinoids with hypergastrinemia.Hepatogastroenterology. 2010 Mar-Apr;57(98):379-82. Hepatogastroenterology. 2010. PMID: 20583448
-
[Therapy of carcinoids of the stomach].Langenbecks Arch Chir. 1996;381(1):18-22. doi: 10.1007/BF00184250. Langenbecks Arch Chir. 1996. PMID: 8717170 Review. German.
-
Endocrine tumours of the stomach.Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):659-73. doi: 10.1016/j.bpg.2005.05.002. Best Pract Res Clin Gastroenterol. 2005. PMID: 16253892 Review.
Cited by
-
Endoscopic mucosal resection: still a reliable therapeutic option for gastrointestinal neuroendocrine tumors.BMC Gastroenterol. 2021 May 24;21(1):238. doi: 10.1186/s12876-021-01821-6. BMC Gastroenterol. 2021. PMID: 34030644 Free PMC article.
-
Clinical features and outcomes of gastric neuroendocrine tumors after endoscopic diagnosis and treatment: A Digestive Endoscopy Society of Tawian (DEST).Medicine (Baltimore). 2018 Sep;97(38):e12101. doi: 10.1097/MD.0000000000012101. Medicine (Baltimore). 2018. PMID: 30235663 Free PMC article.
-
Long-term follow up of endoscopic resection for type 3 gastric NET.World J Gastroenterol. 2013 Dec 14;19(46):8703-8. doi: 10.3748/wjg.v19.i46.8703. World J Gastroenterol. 2013. PMID: 24379589 Free PMC article.
-
Surgical treatment of gastrointestinal neuroendocrine tumors.Langenbecks Arch Surg. 2011 Mar;396(3):299-311. doi: 10.1007/s00423-011-0741-7. Epub 2011 Feb 1. Langenbecks Arch Surg. 2011. PMID: 21279821 Review.
-
Review of the pathogenesis, diagnosis, and management of type I gastric carcinoid tumor.World J Surg. 2011 Aug;35(8):1879-86. doi: 10.1007/s00268-011-1137-0. World J Surg. 2011. PMID: 21559999 Review.
References
-
- Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol. 2004;99:23–32. - PubMed
-
- Soga J. Gastric carcinoids: a statistical evaluation of 1,094 cases collected from the literature. Surg Today. 1997;27:892–901. - PubMed
-
- Hakanson R, Owman C. Concomitant histochemical demonstration of histamine and catecholamines in enterochromaffin-like cells of gastric mucosa. Life Sci. 1967;6:759–766. - PubMed
-
- Solcia E, Rindi G, Silini E, et al. Enterochromaffin-like (ECL) cells and their growths: relationships to gastrin, reduced acid secretion and gastritis. Baillieres Clin Gastroenterol. 1993;7:149–165. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical